| Naringin attenuates renal interstitial fibrosis by regulating the TGF‑β/Smad signaling pathway and inflammation R Wang, G Wu, T Dai, Y Lang, Z Chi, S Yang, D Dong Experimental and Therapeutic Medicine 21 (1), 1-1, 2021 | 39 | 2021 |
| What is value in health and healthcare? A systematic literature review of value assessment frameworks M Zhang, Y Bao, Y Lang, S Fu, M Kimber, M Levine, F Xie Value in health 25 (2), 302-317, 2022 | 21 | 2022 |
| Cetuximab plus chemotherapy versus chemotherapy alone in recurrent or metastatic head and neck squamous cell carcinoma: a cost-effectiveness analysis Y Lang, D Dong Cancer Management and Research, 11383-11390, 2020 | 12 | 2020 |
| Methotrexate (MTX) plus hydroxychloroquine versus MTX plus leflunomide in patients with MTX-resistant active rheumatoid arthritis: a 2-year cohort study in real world L Zhang, F Chen, S Geng, X Wang, L Gu, Y Lang, T Li, S Ye Journal of inflammation research, 1141-1150, 2020 | 11 | 2020 |
| Pembrolizumab vs the EXTREME regimen in recurrent or metastatic head and neck squamous cell carcinoma: a cost-effectiveness analysis Y Lang, D Dong, B Wu Clinical Drug Investigation 40, 1137-1146, 2020 | 11 | 2020 |
| Atezolizumab plus chemotherapy vs. Chemotherapy in advanced or metastatic triple-negative breast cancer: A cost-effectiveness analysis X Liu, Y Lang, Y Liao, Y Zhu Frontiers in Public Health 9, 756899, 2021 | 7 | 2021 |
| Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer Y Lang, Q Chai, W Tao, Y Liao, X Liu, B Wu The Breast 68, 173-180, 2023 | 5 | 2023 |
| Economic evaluation of trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer in the United States Y Lang, B Wu, X Liu Breast Cancer: Targets and Therapy, 453-463, 2022 | 4 | 2022 |
| Budget impact analysis of the introduction of a trastuzumab biosimilar for HER2-positive breast cancer in China Q Chai, H Wen, Y Lang, L Zhang, Y Song, X Liu Clinical Drug Investigation 42 (11), 937-947, 2022 | 2 | 2022 |
| Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis X Liu, Y Lang, Q Chai, Y Lin, Y Liao, Y Zhu Frontiers in Pharmacology 13, 872196, 2022 | 2 | 2022 |
| Patient Preference for Biologic Treatments of Psoriasis in the Chinese Setting Y Lang, B Wu, Z Sun, E Ye, G Dou, X Guan Patient preference and adherence, 1071-1084, 2022 | 1 | 2022 |
| Comparison of evaluation system for clinical value of antineoplastic agents at home and abroad Y LANG, Q CHAI, Y LIAO, X LIU, Y HU China Pharmacy, 1287-1294, 2022 | 1 | 2022 |
| Comparison of commonly used judgment criteria for potentially inappropriate medication in the elderly Y LIAO, Y LANG, Y LIN, X LIU China Pharmacy, 1131-1135, 2022 | 1 | 2022 |
| Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer Y Lang, Y Lin, M Deng, X Liu BMC cancer 24 (1), 236, 2024 | | 2024 |
| The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis F Chen, Y Lang, S Geng, X Wang, L Lu, S Ye, L Zhang, T Li Clinical Rheumatology 42 (10), 2777-2786, 2023 | | 2023 |
| Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis Y Lang, Y Lin, D Li, J Liu, X Liu Cancer Medicine 12 (18), 18447-18459, 2023 | | 2023 |
| Pharmacoeconomic evaluation of clopidogrel versus aspirin for secondary prevention of ischemic stroke Y LANG, C ZHU, W TAO, Y LIAO, C ZHANG, X LIU, B WU China Pharmacy, 837-843, 2023 | | 2023 |
| Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis F Chen, Y Lang, S Geng, X Wang, L Lu, S Ye, L Zhang, T Li Clinical Rheumatology 42 (10), 2923, 2023 | | 2023 |
| The effective threshold dose of etanercept biosimilars in patients with methotrexate-resistant rheumatoid arthritis F Chen, Y Lang, S Geng, X Wang, L Lu, S Ye, L Zhang, T Li | | 2022 |
| Pembrolizumab in head and neck cancer cost effective in US, not in China Y Lang PharmacoEconomics & Outcomes News 865, 25-31, 2020 | | 2020 |
